A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study ...

For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a ...